← All trials
NCT05001516
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Apr 10, 2023
- Completion date
- May 5, 2024
- First posted
- Aug 12, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 42
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- LaNova Medicines LimitedLead sponsor
- University of ToledoOverall official - principal investigator
- City of Hope National Medical CenterOverall official - principal investigator
- Horizon Oncology Research, Inc.Overall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Mercy Clinic Oncology and HematologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.